COMMUNIQUÉS West-GlobeNewswire

argenx reports half year 2019 financial results and second quarter business update
01/08/2019
Enrollment on track for Phase 3 ADAPT trial of efgartigimod (ARGX-113) in generalized myasthenia gravis (gMG) patients with topline results expected in 2H20 First of two registration trials from Phase 3 program of [...]
Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress
01/08/2019
Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress Valneva regains control of key R&D assets, Strengthens financial outlook with $23 million CEPI chikungunya grant [...]
Valneva: résultats financiers du S1 2019 soutenus par une forte performance opérationnelle et des avancées majeures
01/08/2019
Valneva: résultats financiers du S1 2019 soutenus par une forte performance opérationnelle et des avancées majeures Valneva reprend le contrôle de ses actifs R&D et renforce ses perspectives financières grâce à un [...]
Diversicare to Announce Second Quarter 2019 Financial Results on Monday, August 5, 2019
01/08/2019
BRENTWOOD, Tenn., July 31, 2019 (GLOBE NEWSWIRE) -- Diversicare Healthcare Services, Inc. (NASDAQ:DVCR) today announced that it is moving its conference call to Monday, August 5, 2019 at 5:00 p.m. ET, 4:00 p.m. CT. [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/08/2019
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2019, that were previously [...]
Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results
31/07/2019
Completed Enrollment in Phase 3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Head-to-Head Study in Patients Treated with Eculizumab; Top-line Data Anticipated in December 2019 Expects to Initiate Phase 3 Cold Agglutinin [...]
Sarepta Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Corporate Developments on August 7, 2019
31/07/2019
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2019 financial results after the [...]
Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference
31/07/2019
SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena [...]
Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update
31/07/2019
HOPKINTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update
31/07/2019
HIGH POINT, N.C., July 31, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019, and provided an update on recent achievements and [...]
Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
31/07/2019
SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston [...]
Novavax and Catalent Announce Closing of Strategic Partnership
31/07/2019
GAITHERSBURG, Md., July 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon [...]
Clearside Biomedical to Report Second Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, August 7, 2019
31/07/2019
ALPHARETTA, Ga., July 31, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Profound Medical to Present at the Canaccord Genuity 39th Annual Growth Conference
31/07/2019
TORONTO, July 31, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic [...]
CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7
31/07/2019
NEWARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]
Amedisys Reports Second Quarter 2019 Financial Results and Updates 2019 Guidance
31/07/2019
BATON ROUGE, La., July 31, 2019 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2019. Three Month Periods Ended June 30, 2019 and [...]
Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers
31/07/2019
SEATTLE, July 31, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune [...]
Inovalon Reports Second Quarter 2019 Results
31/07/2019
Second Quarter 2019 Highlights Q2 revenue of $157.0 million, up 3% year-over-year, and up 8% sequentially Q2 net income of $4.5 million, resulting in diluted net income of $0.03 per share Q2 Non-GAAP net income of $19.1 [...]
TRACON to Report Second Quarter 2019 Company Highlights and Financial Results on August 7, 2019
31/07/2019
SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer [...]

Pages